513 Spam-Free Article(s) Found
Symbol Name Last Close Mkt Cap DailyStocks'
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Thursday’s Close
GSK GlaxoSmithKline PLC $39.21 $97.25B N/A
Article Searches
Bausch (BHC) Q4 Earnings Beat Estimates, Revenues Down Y/Y http://www.zacks.com/stock/news/356274/bausch-bhc-q4-earnings-beat-estimates-revenues-down-y-y?cid=CS-ZC-FT-356274 Feb 21, 2019 - Bausch (BHC) Q4 earnings and revenues surpass estimates. However, guidance for 2019 is not impressive.
Merck Gets Priority Review for Keytruda in Third-Line SCLC http://www.zacks.com/stock/news/355982/merck-gets-priority-review-for-keytruda-in-third-line-sclc?cid=CS-ZC-FT-355982 Feb 21, 2019 - Merck's (MRK) sBLA looking for approval of Keytruda monotherapy for the third-line treatment of small cell lung cancer, a difficult-to-treat cancer, gets FDA's priority review.
Novo Nordisk Gets FDA Nod for Haemophilia Drug Esperoct http://www.zacks.com/stock/news/355654/novo-nordisk-gets-fda-nod-for-haemophilia-drug-esperoct?cid=CS-ZC-FT-355654 Feb 20, 2019 - Novo Nordisk (NVO) clinches the FDA approval for its biologics license application in favor of Esperoct to treat adults and children suffering haemophilia A.
Bayer Obtains Full Rights to Vitrakvi From Lilly's Loxo http://www.zacks.com/stock/news/355437/bayer-obtains-full-rights-to-vitrakvi-from-lillys-loxo?cid=CS-ZC-FT-355437 Feb 19, 2019 - Bayer (BAYRY) obtains full exclusive licensing rights for the global development and commercialization of Vitrakvi (larotrectinib) and BAY 2731954 (LOXO-195) from Loxo.
New Strong Buy Stocks for February 19th http://www.zacks.com/commentary/213873/new-strong-buy-stocks-for-february-19th?cid=CS-ZC-FT-213873 Feb 19, 2019 - New Strong Buy Stocks for February 19th
Top Ranked Growth Stocks to Buy for February 15th http://www.zacks.com/commentary/213938/top-ranked-growth-stocks-to-buy-for-february-15th?cid=CS-ZC-FT-213938 Feb 15, 2019 - Top Ranked Growth Stocks to Buy for February 15th
Johnson & Johnson (JNJ) to Acquire Auris Health for $3.4B http://www.zacks.com/stock/news/354868/johnson-johnson-jnj-to-acquire-auris-health-for-%2434b?cid=CS-ZC-FT-354868 Feb 14, 2019 - Johnson & Johnson (JNJ) entered into a definitive agreement to acquire Auris Health, Inc., a developer of robotic technologies focused on lung cancer, for approximately $3.4 billion in cash.
Top Ranked Income Stocks to Buy for February 14th http://www.zacks.com/commentary/213612/top-ranked-income-stocks-to-buy-for-february-14th?cid=CS-ZC-FT-213612 Feb 14, 2019 - Top Ranked Income Stocks to Buy for February 14th
New Strong Buy Stocks for February 14th http://www.zacks.com/commentary/213348/new-strong-buy-stocks-for-february-14th?cid=CS-ZC-FT-213348 Feb 14, 2019 - New Strong Buy Stocks for February 14th
AstraZeneca's (AZN) Q4 Earnings Beat, New Drugs Drive Sales http://www.zacks.com/stock/news/354603/astrazenecas-azn-q4-earnings-beat-new-drugs-drive-sales?cid=CS-ZC-FT-354603 Feb 14, 2019 - AstraZeneca (AZN) beats earnings and sales estimates in the fourth quarter and provides encouraging outlook for 2019. Shares up.

Pages: 1234567891011...52

<<<Page 6>